A new form of specific targeting cancer immunotherapy using anti-tumor monoclonal antibody-conjugated lymphokine-activated killer cells.
Cross-linking of effector T cells to target cancer cells augments their tumor lytic activities. Here we describe a new method of conjugating lymphokine-activated killer (LAK) cells with cancer-specific monoclonal antibody. The LAK cells were biotinylated, treated with avidin, and conjugated with biotinylated monoclonal antibody. These monoclonal antibody-conjugated LAK cells showed specifically enhanced killing activities against anti-tumor antibody-reactive cancer cells, and cold target cells specifically inhibited their activities.
Shiraiwa
H
H
National Cancer Center Research Institute, National Cancer Center Hospital, Tokyo.
Sekine
T
T
Tobisu
K
K
Kakizoe
T
T
Koiso
K
K
D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D002460:Cell Line; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D007700:Kinetics; D013274:Stomach Neoplasms / Q000276:immunology*
D000911:Antibodies, Monoclonal